Tomoko Kita, Yoshiyuki Yabe, Yuki Maruyama, Yuki Tachida, Yoshitake Furuta, Naotoshi Yamamura, Ichiro Furuta, Kohei Yamahara, Masaaki Ishikawa, Koichi Omori, Taro Yamaguchi, Takayuki Nakagawa
Countless therapeutic antibodies are currently available for the treatment of a broad range of diseases. Some target molecules of therapeutic antibodies are involved in the pathogenesis of sensorineural hearing loss (SNHL), suggesting that SNHL may be a novel target for monoclonal antibody (mAb) therapy. When considering mAb therapy for SNHL, understanding of the pharmacokinetics of mAbs after local application into the middle ear is crucial. To reveal the fundamental characteristics of mAb pharmacokinetics following local application into the middle ear of guinea pigs, we performed pharmacokinetic analyses of mouse monoclonal antibodies to FLAG-tag (FLAG-mAbs), which have no specific binding sites in the middle and inner ear...
February 2024: Hearing Research